Here’s what you need to know.
1. In the first quarter of 2018, Stryker’s shares declined 7.6 percent. Zacks Consensus Estimate puts each share around $7.82, a 0.1 percent drop.
2. Stryker has been struggling since the fourth quarter of 2017 when the company’s adjusted gross margin fell flat year-over-year at 66.4 percent.
3. Stryker’s spine business also experienced supply issues. The company expects supply issues may remain until later this year.
4. Currently, Zacks gives Stryker shares a sell rating. It noted the company’s debt is now up to $7.2 billion.
More articles on devices and implants:
‘Microjoint’ may postpone hip replacements by a decade or more: 4 insights
Dr. Michael Hisey to present findings from Zimmer Biomet Mobi-C post-hoc analysis — 5 highlights
Medtronic taps new VP of global clinical research and analytics: 4 highlights
